{"preliminary_commentary":{"by_channel":{"x_thread":10},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03525262\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[],"indication":"localized prostate cancer","name":"POTEN-C","nct_id":"NCT03525262","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=poten-c-nct03525262. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"POTEN-C","arms":[{"description":"* GTV represents MR defined dominant radiographic disease, if identifiable.\n* CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.\n* PTV1\\_30Gy will not be used or created on this arm\n* PTV2\\_SAbR40Gy OR PTV2\\_SAbR45Gy will be generated by a 3mm expansion on the CTV. PTV2\\_SAbR will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy).","label":"SAbR WITHOUT Neurovascular sparing","type":"NO_INTERVENTION"},{"description":"* GTV represents MR defined dominant radiographic disease, if identifiable.\n* CTV encompasses the full prostate. At physician's discretion, the insertion of the seminal vesicle upon the prostate on slices containing prostate may be included.\n* PTV1\\_30Gy represents a 3mm expansion on the CTV, excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).\n* PTV2\\_SAbR40Gy OR PTV2\\_SAbR45Gy will be generated by subtracting a 5mm expansion around the neurovascular elements to be spared (at least one side, left or right) from PTV1. These neurovascular structures consist of the neurovascular bundle, penile bulb, and internal pudendal arteries (see 4.1.5.2.16). PTV2 will receive 8-9 Gy per fraction for 5 fractions (40-45 Gy).","label":"SAbR WITH Neurovascular sparing","type":"EXPERIMENTAL"}],"collaborators":["Boston Scientific Corporation"],"completion_date":{"date":"2029-04","type":"ESTIMATED"},"conditions":["Prostate Cancer Adenocarcinoma"],"enrollment":{"count":124,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"30Gy (Gray) planning target volume (PTV)","otherNames":[],"type":"RADIATION"}],"last_update":"2026-06-05","lead_sponsor":"University of Texas Southwestern Medical Center","official_title":"A Phase II Randomized Controlled Trial of Stereotactic Ablative Body Radiotherapy (SAbR) With or Without Neurovascular Sparing for Erectile Function Preservation in Localized Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To compare the decline in patient health-related quality of life.","timeFrame":"Mean 24-Months"}],"references":[],"start_date":{"date":"2018-04-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)","url":"https://clinicaltrials.gov/study/NCT03525262"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/poten-c-nct03525262"}